WINSTON-SALEM, NC, Sept. 8, 2022 (GLOBE NEWSWIRE) — ProKidney Corp. PROC (“ProKidney”), a leader in late-stage cellular therapeutics focused on chronic kidney disease (CKD), announced today that Dr. Tim Bertram, Chief Executive Officer of ProKidney, will participate in a fireside chat on Wednesday, September 14. 2022, at the MorganStanley20th Annual global health conference, in New York, New York. During the fireside chat, ProKidney plans to discuss its commercialization strategies and potential product line expansions to expand market access, approaches to lowering the cost of goods and scaling manufacturing to meet future market demand.
Access to the live webcast is available on the Events and Presentations section of ProKidney’s Investor Relations website at https://investors.prokidney.com/news-events/events-and-presentations. In addition to the webcast, a new corporate presentation with updated information on the addressable market and opportunities for REACT™ is now available on the company’s IR website.
Investors attending the conference and interested in meeting ProKidney’s management may request a meeting by contacting their Morgan Stanley representative.
About ProKidney
ProKidney, a pioneer in treating CKD through innovations in cell therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a unique, patented, autologous cell therapy with the potential not only to slow and stabilize the progression of chronic kidney disease, but in some cases potentially to drive meaningful improvement in renal function . Late stage CKD, stage 3b-4, is an important target for REACT™ therapy. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) status, FDA and EMA guidelines, supporting its ongoing Phase 3 clinical program, which started in January 2022. For more information, see www.prokidney.com.
About CKD
There are no therapies that…
